Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sargramostim

A recombinant therapeutic agent which is chemically identical to or similar to endogenous human GM-CSF. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:23-L-leucine colony-stimulating factor 2
colony stimulating factor 2
CSF-2
GM-CSF
granulocyte macrophage colony-stimulating factor
sargramostatin
US brand name:Leukine
Prokine
Abbreviation:GM CSF
GM-CSF
rhu GM-CFS
Code name:DRG-0012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search